Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Public ClinicalTrials.gov record NCT00554827. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-label Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Study identification
- NCT ID
- NCT00554827
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Acrotech Biopharma Inc.
- Industry
- Enrollment
- 55 participants
Conditions and interventions
Conditions
Interventions
- Vitamin B12 Dietary Supplement
- Folic Acid Dietary Supplement
- Pralatrexate Drug
Dietary Supplement · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2007
- Primary completion
- Dec 31, 2011
- Completion
- Jan 31, 2012
- Last update posted
- Jan 2, 2020
2007 – 2012
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| Stanford University School of Medicine | Redwood City | California | 94063 | — |
| Yale University School of Medicine | New Haven | Connecticut | 06519 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10017 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77080-4009 | — |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00554827, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 2, 2020 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00554827 live on ClinicalTrials.gov.